

Leverett

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	2.1	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	8	7.3	109.7	(47.2-216.1)	Female	1	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	2.9	nc	(nc-nc)	Female	3	0.7	nc	(nc-nc)
Female	2	2.0	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.7	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	12	9.1	131.5	(67.9-229.7)
Male	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	2	0.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.2	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<u>Testis</u>				
Female	2	0.5	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.8	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	24	30.6	78.5	(50.3-116.7)
Male	1	0.7	nc	(nc-nc)	Female	24	23.0	104.2	(66.7-155.0)
Female	0	0.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	1	4.0	nc	(nc-nc)					
Female	5	2.9	172.2	(55.5-401.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lexington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	35	43.5	80.5	(56.1-112.0)	Male	41	25.7	159.4	(114.4-216.3)
Female	16	16.7	95.8	(54.7-155.6)	Female	25	19.8	126.1	(81.6-186.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	11	7.5	146.1	(72.8-261.4)	Male	8	6.8	118.0	(50.8-232.5)
Female	5	6.3	79.1	(25.5-184.7)	Female	8	5.4	147.0	(63.3-289.6)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	1.2	nc	(nc-nc)	Male	17	22.7	75.0	(43.7-120.1)
Female	189	154.0	122.8	(105.9-141.6)	Female	17	20.5	83.0	(48.3-133.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	5.6	nc	(nc-nc)	Male	11	15.6	70.7	(35.2-126.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	39	54.0	72.3	(51.4-98.8)	Female	9	15.0	59.9	(27.3-113.7)
Female	42	56.6	74.2	(53.4-100.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	9	13.5	66.8	(30.5-126.9)
Male	7	11.0	63.7	(25.5-131.3)	Female	11	15.0	73.1	(36.4-130.8)
Female	6	3.2	185.4	(67.7-403.4)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	159	154.4	103.0	(87.6-120.3)
Male	2	2.7	nc	(nc-nc)	<u>Stomach</u>				
Female	3	2.2	nc	(nc-nc)	Male	6	10.3	58.5	(21.3-127.3)
<u>Kidney & Renal Pelvis</u>					Female	4	6.5	nc	(nc-nc)
Male	12	21.2	56.7	(29.3-99.0)	<u>Testis</u>				
Female	4	12.8	nc	(nc-nc)	Male	2	3.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	6.3	nc	(nc-nc)	Male	11	7.1	156.0	(77.8-279.1)
Female	0	1.8	nc	(nc-nc)	Female	25	22.0	113.9	(73.7-168.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	16	14.4	110.9	(63.4-180.2)	Female	24	34.4	69.8	(44.7-103.9)
Female	16	11.3	141.5	(80.8-229.7)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	472	553.6	85.3	(77.7-93.3)
Male	7	10.9	64.3	(25.8-132.5)	Female	505	546.1	92.5	(84.6-100.9)
Female	3	4.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	42	78.5	53.5	(38.5-72.3)					
Female	48	79.7	60.2	(44.4-79.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Leyden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	0.8	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	2	2.9	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	1.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	1	0.2	nc	(nc-nc)	Male	7	3.3	209.8	(84.0-432.2)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.5	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.1	nc	(nc-nc)	Male	13	11.4	114.2	(60.7-195.3)
Female	0	0.0	nc	(nc-nc)	Female	7	9.2	76.4	(30.6-157.3)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.3	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	0	0.2	nc	(nc-nc)	Male	13	11.4	114.2	(60.7-195.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.3	nc	(nc-nc)	Female	7	9.2	76.4	(30.6-157.3)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.4	nc	(nc-nc)	Male	13	11.4	114.2	(60.7-195.3)
Female	0	1.1	nc	(nc-nc)	Female	7	9.2	76.4	(30.6-157.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lincoln

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	7.7	nc	(nc-nc)	Male	5	5.0	99.4	(32.0-232.1)
Female	1	2.5	nc	(nc-nc)	Female	6	3.8	156.0	(57.0-339.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.6	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	5	4.4	113.3	(36.5-264.5)
Female	31	28.0	110.9	(75.3-157.4)	Female	0	3.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.2	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	6	9.9	60.5	(22.1-131.8)	Female	0	2.6	nc	(nc-nc)
Female	4	8.3	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	2.5	nc	(nc-nc)
Male	2	2.1	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	33	29.3	112.7	(77.6-158.3)
Male	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.5	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.9	nc	(nc-nc)
Male	4	4.1	nc	(nc-nc)	<u>Testis</u>				
Female	5	2.2	224.2	(72.3-523.3)	Male	2	1.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.2	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	6	5.1	118.1	(43.1-257.0)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	2.8	nc	(nc-nc)	Female	6	6.2	96.4	(35.2-209.8)
Female	2	2.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	88	105.0	83.8	(67.2-103.2)
Male	2	2.1	nc	(nc-nc)	Female	83	93.6	88.6	(70.6-109.9)
Female	0	0.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	5	14.4	34.8	(11.2-81.3)					
Female	13	12.8	101.8	(54.2-174.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Littleton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	8.8	79.4	(31.8-163.6)	Male	9	5.8	154.3	(70.4-292.9)
Female	1	3.2	nc	(nc-nc)	Female	3	4.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.8	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	5	5.0	99.0	(31.9-231.1)
Female	34	33.5	101.6	(70.3-141.9)	Female	5	4.1	121.5	(39.2-283.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.5	nc	(nc-nc)	Male	1	3.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	13	11.4	113.5	(60.4-194.2)	Female	2	3.2	nc	(nc-nc)
Female	10	10.8	92.5	(44.3-170.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	2.8	nc	(nc-nc)
Male	1	2.4	nc	(nc-nc)	Female	3	2.8	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	35	33.5	104.5	(72.8-145.4)
Male	1	0.8	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.6	nc	(nc-nc)	Male	0	2.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.2	nc	(nc-nc)
Male	6	4.8	125.7	(45.9-273.6)	<u>Testis</u>				
Female	0	2.7	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.4	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	3	5.8	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	3.2	nc	(nc-nc)	Female	7	7.4	94.1	(37.7-193.9)
Female	5	2.4	209.8	(67.6-489.7)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	100	120.2	83.2	(67.7-101.2)
Male	0	2.5	nc	(nc-nc)	Female	99	114.1	86.8	(70.5-105.6)
Female	0	0.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	6	16.2	37.0	(13.5-80.5)					
Female	11	15.5	70.8	(35.3-126.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Longmeadow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	21.9	86.9	(52.3-135.7)	Male	19	13.1	145.5	(87.5-227.2)
Female	5	8.3	60.3	(19.4-140.7)	Female	15	10.0	150.1	(84.0-247.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	3.8	132.0	(42.5-308.1)	Male	3	3.5	nc	(nc-nc)
Female	1	3.2	nc	(nc-nc)	Female	1	2.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	17	11.5	148.2	(86.3-237.3)
Female	83	76.6	108.4	(86.3-134.4)	Female	7	10.2	68.4	(27.4-140.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.8	nc	(nc-nc)	Male	3	8.0	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	20	27.5	72.7	(44.4-112.3)	Female	9	7.5	119.5	(54.5-226.9)
Female	16	28.6	55.9	(32.0-90.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	6.8	nc	(nc-nc)
Male	8	5.6	143.8	(61.9-283.3)	Female	6	7.5	79.9	(29.2-174.0)
Female	2	1.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	92	78.8	116.7	(94.1-143.1)
Male	2	1.4	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.1	nc	(nc-nc)	Male	3	5.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	3.3	nc	(nc-nc)
Male	14	10.7	130.7	(71.4-219.3)	<u>Testis</u>				
Female	5	6.3	78.9	(25.4-184.2)	Male	4	1.8	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	3.2	nc	(nc-nc)	Male	5	3.6	140.1	(45.2-327.0)
Female	1	0.9	nc	(nc-nc)	Female	10	11.0	90.6	(43.4-166.7)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	7.4	68.0	(21.9-158.6)	Female	18	17.2	104.8	(62.1-165.7)
Female	3	5.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	255	280.8	90.8	(80.0-102.7)
Male	2	5.6	nc	(nc-nc)	Female	237	272.3	87.0	(76.3-98.9)
Female	0	2.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	22	39.2	56.1	(35.1-84.9)					
Female	31	38.9	79.6	(54.1-113.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lowell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	89	81.8	108.8	(87.4-133.9)	Male	19	56.2	33.8	(20.3-52.8)
Female	34	34.4	98.7	(68.4-137.9)	Female	21	49.6	42.3	(26.2-64.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	15	19.1	78.4	(43.8-129.3)	Male	9	13.3	67.4	(30.8-128.0)
Female	15	16.3	91.8	(51.3-151.4)	Female	12	11.2	106.9	(55.2-186.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	4	2.3	nc	(nc-nc)	Male	45	49.1	91.7	(66.9-122.7)
Female	276	339.4	81.3	(72.0-91.5)	Female	42	44.5	94.4	(68.0-127.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	20	15.3	130.6	(79.7-201.7)	Male	60	33.8	177.7	(135.6-228.8)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	129	106.3	121.4	(101.4-144.3)	Female	32	33.3	96.0	(65.7-135.5)
Female	125	116.4	107.4	(89.4-128.0)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	21	22.0	95.4	(59.1-145.9)	Male	23	26.0	88.4	(56.0-132.7)
Female	7	6.7	104.4	(41.8-215.1)	Female	28	30.6	91.5	(60.8-132.2)
<u>Hodgkin Lymphoma</u>					<u>Stomach</u>				
Male	9	10.3	87.7	(40.0-166.4)	Male	17	19.9	85.2	(49.6-136.5)
Female	4	7.9	nc	(nc-nc)	Female	10	13.2	76.0	(36.4-139.7)
<u>Kidney & Renal Pelvis</u>					<u>Testis</u>				
Male	52	44.9	115.8	(86.5-151.9)	Male	10	17.6	56.9	(27.2-104.7)
Female	37	28.2	131.0	(92.2-180.5)	<u>Thyroid</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	18	12.6	142.5	(84.4-225.2)	Female	80	74.8	107.0	(84.8-133.1)
Female	7	3.8	183.5	(73.5-378.0)	<u>All Sites / Types</u>				
<u>Leukemia</u>					<u>Liver and Intrahepatic Bile Ducts</u>				
Male	43	31.9	135.0	(97.7-181.8)	Male	46	22.8	202.2	(148.0-269.7)
Female	26	26.3	98.9	(64.6-144.9)	Female	12	8.5	140.5	(72.5-245.4)
<u>Lung and Bronchus</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	197	150.9	130.6	(113.0-150.1)	Female	80	74.8	107.0	(84.8-133.1)
Female	169	167.7	100.8	(86.1-117.1)	Male	1162	1137.9	102.1	(96.3-108.2)
					Female	1137	1205.2	94.3	(88.9-100.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ludlow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	23	24.8	92.8	(58.8-139.2)	Male	9	16.1	55.9	(25.5-106.2)
Female	6	9.2	65.3	(23.9-142.2)	Female	10	11.9	83.9	(40.2-154.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	4.9	142.1	(56.9-292.9)	Male	2	4.0	nc	(nc-nc)
Female	7	3.8	185.3	(74.2-381.9)	Female	3	3.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	7	13.9	50.3	(20.1-103.6)
Female	83	88.3	94.0	(74.9-116.6)	Female	13	11.6	112.3	(59.7-192.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.5	nc	(nc-nc)	Male	5	9.8	50.8	(16.4-118.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	33	31.6	104.4	(71.8-146.6)	Female	2	8.6	nc	(nc-nc)
Female	23	30.3	75.9	(48.1-113.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	10	7.9	127.3	(60.9-234.1)
Male	4	6.6	nc	(nc-nc)	Female	9	8.1	110.8	(50.6-210.4)
Female	1	1.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	100	94.5	105.8	(86.1-128.7)
Male	5	2.4	207.3	(66.8-483.8)	<u>Stomach</u>				
Female	1	1.6	nc	(nc-nc)	Male	9	6.0	151.1	(68.9-286.8)
<u>Kidney & Renal Pelvis</u>					Female	4	3.4	nc	(nc-nc)
Male	16	13.1	122.3	(69.9-198.6)	<u>Testis</u>				
Female	4	7.4	nc	(nc-nc)	Male	5	3.9	128.2	(41.3-299.1)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	3.8	nc	(nc-nc)	Male	4	5.0	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	11	14.1	78.1	(38.9-139.8)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	11	8.7	126.3	(63.0-226.0)	Female	12	20.0	59.9	(30.9-104.6)
Female	4	6.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	332	335.7	98.9	(88.5-110.1)
Male	10	6.7	148.9	(71.3-273.8)	Female	242	311.2	77.8	(68.3-88.2)
Female	0	2.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	46	45.8	100.3	(73.4-133.8)					
Female	28	45.7	61.3	(40.7-88.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lunenburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	10.4	134.3	(73.4-225.4)	Male	6	7.0	85.5	(31.2-186.2)
Female	2	3.4	nc	(nc-nc)	Female	3	5.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.2	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
Female	4	1.6	nc	(nc-nc)	Female	5	1.2	433.0	(139.5-1010.5)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	2	6.1	nc	(nc-nc)
Female	32	39.3	81.4	(55.7-114.9)	Female	5	4.6	109.3	(35.2-255.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.7	nc	(nc-nc)	Male	3	4.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	7	13.7	51.0	(20.4-105.0)	Female	3	3.7	nc	(nc-nc)
Female	8	11.6	68.8	(29.6-135.5)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	3	2.9	nc	(nc-nc)	Male	51	41.1	123.9	(92.3-163.0)
Female	2	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.9	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	5.8	85.8	(27.6-200.2)	Female	9	8.8	102.1	(46.6-193.9)
Female	2	3.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Female</u>				
Male	3	1.7	nc	(nc-nc)	Male	140	145.1	96.5	(81.2-113.9)
Female	0	0.4	nc	(nc-nc)	Female	117	129.8	90.1	(74.5-108.0)
<u>Leukemia</u>					<u>Male</u>				
Male	4	3.8	nc	(nc-nc)	<u>Female</u>				
Female	2	2.6	nc	(nc-nc)	<u>Male</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Female</u>				
Male	2	3.0	nc	(nc-nc)	<u>Male</u>				
Female	1	0.9	nc	(nc-nc)	<u>Female</u>				
<u>Lung and Bronchus</u>					<u>Male</u>				
Male	23	19.4	118.4	(75.0-177.6)	<u>Female</u>				
Female	19	17.5	108.6	(65.3-169.6)	<u>Male</u>				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lynn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	79	83.0	95.1	(75.3-118.6)	Male	40	53.9	74.3	(53.1-101.1)
Female	35	32.3	108.5	(75.6-150.9)	Female	31	45.4	68.3	(46.4-97.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	17	17.7	95.8	(55.8-153.4)	Male	15	13.3	113.1	(63.3-186.6)
Female	16	14.9	107.3	(61.3-174.2)	Female	8	10.6	75.8	(32.7-149.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	2.3	nc	(nc-nc)	Male	43	47.3	90.9	(65.8-122.4)
Female	270	317.6	85.0	(75.2-95.8)	Female	47	41.4	113.4	(83.3-150.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	17	13.8	123.3	(71.8-197.5)	Male	46	32.1	143.1	(104.8-190.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	98	105.7	92.7	(75.3-113.0)	Female	36	31.1	115.6	(81.0-160.1)
Female	102	108.7	93.8	(76.5-113.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	27	26.1	103.6	(68.3-150.8)
Male	30	21.6	139.0	(93.8-198.4)	Female	32	28.7	111.5	(76.2-157.3)
Female	9	6.3	143.5	(65.5-272.5)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	285	302.9	94.1	(83.5-105.7)
Male	8	8.7	91.8	(39.5-181.0)	<u>Stomach</u>				
Female	4	6.8	nc	(nc-nc)	Male	28	20.0	140.0	(93.0-202.3)
<u>Kidney & Renal Pelvis</u>					Female	23	12.3	187.5	(118.8-281.3)
Male	40	43.2	92.5	(66.1-126.0)	<u>Testis</u>				
Female	34	26.4	128.9	(89.2-180.1)	Male	6	14.2	42.3	(15.4-92.0)
<u>Larynx</u>					<u>Thyroid</u>				
Male	13	12.4	105.2	(56.0-179.9)	Male	8	17.0	47.1	(20.3-92.9)
Female	4	3.6	nc	(nc-nc)	Female	52	56.0	92.9	(69.4-121.8)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	37	31.0	119.3	(84.0-164.4)	Female	85	70.8	120.1	(95.9-148.5)
Female	26	24.3	107.1	(69.9-156.9)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	1113	1112.9	100.0	(94.2-106.1)
Male	27	22.0	122.8	(80.9-178.6)	Female	1154	1123.1	102.8	(96.9-108.9)
Female	6	8.0	75.0	(27.4-163.2)					
<u>Lung and Bronchus</u>									
Male	171	151.2	113.1	(96.8-131.4)					
Female	181	157.7	114.8	(98.7-132.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lynnfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	17.1	99.5	(57.9-159.4)	Male	16	10.2	157.0	(89.7-255.0)
Female	3	5.5	nc	(nc-nc)	Female	8	7.0	114.4	(49.3-225.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.0	nc	(nc-nc)	Male	3	2.7	nc	(nc-nc)
Female	1	2.2	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	8	8.9	89.5	(38.5-176.3)
Female	71	54.4	130.6	(102.0-164.7)	Female	6	6.9	86.9	(31.7-189.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.0	nc	(nc-nc)	Male	2	6.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	24	21.2	113.0	(72.4-168.1)	Female	7	5.3	133.2	(53.4-274.5)
Female	15	18.1	82.9	(46.4-136.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	5.3	nc	(nc-nc)
Male	3	4.4	nc	(nc-nc)	Female	2	4.8	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	74	62.7	118.1	(92.7-148.3)
Male	2	1.1	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.8	nc	(nc-nc)	Male	1	4.0	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	3	2.0	nc	(nc-nc)
Male	7	8.4	82.9	(33.2-170.9)	<u>Testis</u>				
Female	3	4.5	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	2.5	nc	(nc-nc)	Male	5	2.8	178.3	(57.4-416.0)
Female	0	0.6	nc	(nc-nc)	Female	12	8.2	146.9	(75.8-256.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	12	5.7	211.6	(109.2-369.7)	Female	14	12.5	111.9	(61.1-187.7)
Female	5	3.7	133.6	(43.0-311.7)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	224	220.7	101.5	(88.7-115.7)
Male	0	4.4	nc	(nc-nc)	Female	200	187.6	106.6	(92.4-122.5)
Female	1	1.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	25	31.2	80.2	(51.9-118.4)					
Female	25	27.4	91.3	(59.1-134.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Malden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	70	57.4	121.9	(95.0-154.0)	Male	20	37.2	53.8	(32.9-83.1)
Female	27	23.0	117.6	(77.5-171.1)	Female	20	31.5	63.5	(38.8-98.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	15	11.6	129.4	(72.4-213.4)	Male	7	9.2	76.3	(30.6-157.2)
Female	9	9.9	91.2	(41.6-173.1)	Female	4	7.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.6	nc	(nc-nc)	Male	25	32.2	77.7	(50.2-114.6)
Female	196	220.9	88.7	(76.7-102.1)	Female	17	29.1	58.4	(34.0-93.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	12	9.6	125.4	(64.7-219.0)	Male	29	21.9	132.2	(88.5-189.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	93	72.9	127.5	(102.9-156.2)	Female	18	21.7	83.1	(49.2-131.3)
Female	76	77.0	98.7	(77.7-123.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	17	18.0	94.6	(55.1-151.5)
Male	18	14.9	121.0	(71.7-191.2)	Female	15	20.4	73.5	(41.1-121.2)
Female	5	4.5	111.8	(36.0-261.0)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	178	211.1	84.3	(72.4-97.7)
Male	5	5.8	86.6	(27.9-202.2)	<u>Stomach</u>				
Female	3	4.5	nc	(nc-nc)	Male	18	13.8	130.4	(77.2-206.1)
<u>Kidney & Renal Pelvis</u>					Female	6	8.7	68.7	(25.1-149.5)
Male	28	29.6	94.4	(62.7-136.5)	<u>Testis</u>				
Female	18	18.5	97.5	(57.8-154.2)	Male	8	9.9	81.0	(34.9-159.6)
<u>Larynx</u>					<u>Thyroid</u>				
Male	5	8.5	58.6	(18.9-136.7)	Male	8	11.7	68.4	(29.5-134.9)
Female	2	2.5	nc	(nc-nc)	Female	38	38.4	99.0	(70.0-135.8)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	18	20.5	88.0	(52.1-139.0)	Female	45	49.3	91.3	(66.6-122.2)
Female	18	16.4	109.5	(64.9-173.1)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	768	767.1	100.1	(93.2-107.5)
Male	30	15.0	199.9	(134.8-285.3)	Female	734	785.4	93.5	(86.8-100.5)
Female	13	5.6	232.6	(123.7-397.7)					
<u>Lung and Bronchus</u>									
Male	109	104.9	103.9	(85.3-125.4)					
Female	118	111.9	105.5	(87.3-126.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Manchester by the Sea

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	7.2	97.7	(39.1-201.3)	Male	9	4.5	200.5	(91.5-380.6)
Female	2	2.6	nc	(nc-nc)	Female	10	3.3	298.5	(142.9-549.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.3	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.9	nc	(nc-nc)
Female	40	26.2	152.7	(109.0-207.9)	Female	2	3.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.0	nc	(nc-nc)	Male	5	2.9	173.5	(55.9-405.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	10	9.2	109.1	(52.2-200.6)	Female	2	2.5	nc	(nc-nc)
Female	12	8.6	139.9	(72.2-244.5)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	3	2.0	nc	(nc-nc)	Male	23	28.5	80.7	(51.1-121.0)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.5	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	3.8	nc	(nc-nc)	Female	3	6.1	nc	(nc-nc)
Female	0	2.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	0	1.1	nc	(nc-nc)	Male	4	2.4	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	5	1.8	284.4	(91.7-663.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	2	2.0	nc	(nc-nc)	Male	9	13.4	67.1	(30.6-127.4)
Female	0	0.6	nc	(nc-nc)	Female	5	12.8	39.2	(12.6-91.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Mansfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	13.8	116.3	(66.4-188.8)	Male	13	10.9	119.6	(63.6-204.5)
Female	8	4.9	162.4	(69.9-320.1)	Female	16	9.8	164.0	(93.7-266.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.9	nc	(nc-nc)	Male	3	2.4	nc	(nc-nc)
Female	2	3.1	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	9	9.4	95.8	(43.7-181.9)
Female	74	63.9	115.7	(90.9-145.3)	Female	5	7.1	70.6	(22.8-164.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.5	nc	(nc-nc)	Male	9	6.8	132.3	(60.4-251.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	22	19.3	114.2	(71.6-172.9)	Female	8	5.9	135.9	(58.5-267.8)
Female	23	17.5	131.7	(83.4-197.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	4.6	109.7	(35.3-255.9)
Male	8	4.0	200.6	(86.4-395.3)	Female	6	4.4	137.9	(50.3-300.1)
Female	0	0.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	60	54.8	109.4	(83.5-140.8)
Male	1	2.1	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.6	nc	(nc-nc)	Male	2	3.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.9	nc	(nc-nc)
Male	8	8.7	91.6	(39.4-180.5)	<u>Testis</u>				
Female	8	4.8	167.7	(72.2-330.4)	Male	7	3.9	181.5	(72.7-373.9)
<u>Larynx</u>					<u>Thyroid</u>				
Male	5	2.3	217.5	(70.1-507.5)	Male	5	4.1	121.6	(39.2-283.7)
Female	2	0.6	nc	(nc-nc)	Female	20	14.3	139.4	(85.1-215.3)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	6.0	100.2	(36.6-218.0)	Female	11	13.4	82.4	(41.1-147.4)
Female	5	4.5	111.9	(36.1-261.2)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	222	206.8	107.3	(93.7-122.4)
Male	6	4.4	136.0	(49.7-296.0)	Female	248	208.0	119.2	(104.8-135.0)
Female	1	1.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	21	25.6	82.0	(50.7-125.4)					
Female	37	24.6	150.2	(105.8-207.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Marblehead

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	24	26.4	90.9	(58.2-135.2)	Male	28	16.4	170.5	(113.3-246.4)
Female	12	9.4	128.1	(66.1-223.9)	Female	26	12.6	207.1	(135.3-303.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	4.9	123.2	(45.0-268.2)	Male	3	4.2	nc	(nc-nc)
Female	11	3.9	281.2	(140.2-503.2)	Female	0	3.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	21	14.3	147.3	(91.2-225.2)
Female	110	95.8	114.8	(94.4-138.4)	Female	13	11.9	109.0	(58.0-186.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	3.8	131.6	(42.4-307.2)	Male	8	10.3	77.7	(33.4-153.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	33	33.6	98.2	(67.6-137.9)	Female	11	9.2	119.8	(59.7-214.4)
Female	35	31.7	110.5	(77.0-153.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	7	8.3	83.9	(33.6-172.8)
Male	2	7.0	nc	(nc-nc)	Female	9	8.3	107.9	(49.2-204.7)
Female	1	1.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	115	100.3	114.6	(94.6-137.6)
Male	1	1.8	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.5	nc	(nc-nc)	Male	3	6.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	4	3.5	nc	(nc-nc)
Male	13	13.6	95.5	(50.8-163.2)	<u>Testis</u>				
Female	7	7.7	90.4	(36.2-186.2)	Male	4	2.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	4.0	nc	(nc-nc)	Male	5	4.7	105.6	(34.0-246.5)
Female	0	1.1	nc	(nc-nc)	Female	9	15.1	59.4	(27.1-112.8)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	8	9.0	88.9	(38.3-175.3)	Female	14	21.6	64.8	(35.4-108.7)
Female	7	6.6	106.7	(42.7-219.8)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	361	350.8	102.9	(92.6-114.1)
Male	6	7.1	84.0	(30.7-182.8)	Female	354	327.6	108.0	(97.1-119.9)
Female	6	2.3	257.8	(94.1-561.2)					
<u>Lung and Bronchus</u>									
Male	34	48.6	70.0	(48.5-97.8)					
Female	40	46.2	86.6	(61.9-118.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Marion

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	7.8	63.8	(20.6-149.0)	Male	6	4.7	128.6	(47.0-279.9)
Female	5	2.7	183.0	(59.0-427.1)	Female	5	3.4	148.6	(47.9-346.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	1.3	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	4.1	nc	(nc-nc)
Female	27	26.1	103.6	(68.3-150.8)	Female	6	3.4	176.6	(64.5-384.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.0	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	9.7	nc	(nc-nc)	Female	5	2.6	196.0	(63.2-457.3)
Female	9	9.1	98.6	(45.0-187.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	2.4	nc	(nc-nc)
Male	4	2.0	nc	(nc-nc)	Female	3	2.4	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	30	28.8	104.3	(70.3-148.9)
Male	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.4	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.0	nc	(nc-nc)
Male	1	3.9	nc	(nc-nc)	<u>Testis</u>				
Female	1	2.2	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.2	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	5	3.8	131.2	(42.3-306.3)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	2.6	nc	(nc-nc)	Female	7	6.0	116.1	(46.5-239.2)
Female	0	1.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	86	101.1	85.1	(68.1-105.1)
Male	2	2.0	nc	(nc-nc)	Female	92	91.5	100.6	(81.1-123.4)
Female	2	0.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	12	14.3	83.9	(43.3-146.5)					
Female	9	13.4	67.1	(30.6-127.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Marlborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	35	35.2	99.4	(69.2-138.2)	Male	14	23.8	58.8	(32.1-98.7)
Female	13	13.6	95.5	(50.8-163.3)	Female	13	19.5	66.7	(35.5-114.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	7.6	105.3	(45.4-207.5)	Male	7	5.7	121.8	(48.8-251.0)
Female	7	6.2	113.8	(45.6-234.5)	Female	4	4.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.0	nc	(nc-nc)	Male	23	20.6	111.7	(70.8-167.6)
Female	130	138.3	94.0	(78.5-111.6)	Female	21	17.5	119.9	(74.2-183.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	11	6.1	179.3	(89.4-320.8)	Male	14	14.5	96.4	(52.6-161.7)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	33	45.9	72.0	(49.5-101.1)	Female	14	13.4	104.6	(57.1-175.5)
Female	35	46.3	75.7	(52.7-105.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	11.2	44.6	(14.4-104.0)
Male	8	9.5	84.4	(36.4-166.4)	Female	16	12.1	131.9	(75.4-214.3)
Female	5	2.6	190.4	(61.3-444.2)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	119	133.4	89.2	(73.9-106.7)
Male	9	3.7	243.7	(111.2-462.7)	<u>Stomach</u>				
Female	5	2.7	182.2	(58.7-425.2)	Male	9	8.6	104.9	(47.9-199.2)
<u>Kidney & Renal Pelvis</u>					Female	2	5.2	nc	(nc-nc)
Male	25	19.2	130.1	(84.2-192.1)	<u>Testis</u>				
Female	11	11.2	97.9	(48.8-175.2)	Male	6	6.3	94.6	(34.5-205.8)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	5.5	nc	(nc-nc)	Male	12	7.8	154.8	(79.9-270.4)
Female	1	1.6	nc	(nc-nc)	Female	32	24.6	130.2	(89.1-183.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	15	13.0	115.5	(64.6-190.6)	Female	31	30.7	100.8	(68.5-143.1)
Female	6	10.1	59.6	(21.8-129.8)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	448	484.0	92.6	(84.2-101.5)
Male	15	9.8	153.2	(85.7-252.6)	Female	491	481.0	102.1	(93.3-111.5)
Female	3	3.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	67	64.6	103.6	(80.3-131.6)					
Female	78	66.1	118.0	(93.2-147.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Marshfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	28	22.3	125.7	(83.5-181.6)	Male	33	15.8	209.3	(144.0-293.9)
Female	15	7.9	189.6	(106.0-312.7)	Female	15	12.8	117.5	(65.7-193.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	5.1	nc	(nc-nc)	Male	5	3.8	131.0	(42.2-305.6)
Female	5	4.0	124.7	(40.2-291.0)	Female	5	2.7	186.7	(60.2-435.6)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.7	nc	(nc-nc)	Male	21	13.5	155.9	(96.5-238.4)
Female	116	94.4	122.9	(101.6-147.4)	Female	15	10.7	140.1	(78.3-231.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	4.2	120.1	(38.7-280.2)	Male	11	10.3	106.8	(53.2-191.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	37	30.0	123.2	(86.7-169.8)	Female	12	8.9	135.4	(69.9-236.6)
Female	30	26.5	113.1	(76.3-161.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	7.3	nc	(nc-nc)
Male	12	6.5	185.1	(95.5-323.3)	Female	7	6.9	101.0	(40.5-208.1)
Female	2	1.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	138	94.1	146.7	(123.2-173.3)
Male	2	2.3	nc	(nc-nc)	<u>Stomach</u>				
Female	3	1.8	nc	(nc-nc)	Male	2	5.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	4	2.9	nc	(nc-nc)
Male	15	13.1	114.3	(63.9-188.5)	<u>Testis</u>				
Female	2	7.3	nc	(nc-nc)	Male	8	3.7	218.6	(94.1-430.8)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	3.8	nc	(nc-nc)	Male	0	5.2	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	15	17.1	87.5	(48.9-144.3)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	12	8.4	142.3	(73.5-248.6)	Female	24	21.5	111.6	(71.5-166.1)
Female	7	6.1	115.2	(46.1-237.3)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	426	324.0	131.5	(119.3-144.6)
Male	7	6.9	101.4	(40.6-208.9)	Female	391	308.2	126.9	(114.6-140.1)
Female	1	2.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	57	42.3	134.6	(102.0-174.4)					
Female	63	41.0	153.6	(118.0-196.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Mashpee

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	34	20.2	168.2	(116.4-235.0)	Male	15	11.7	127.9	(71.5-210.9)
Female	9	6.8	132.2	(60.3-251.0)	Female	10	8.6	116.6	(55.8-214.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.4	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
Female	1	2.8	nc	(nc-nc)	Female	0	2.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	12	10.3	116.5	(60.1-203.5)
Female	82	64.1	127.8	(101.7-158.7)	Female	1	8.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.5	nc	(nc-nc)	Male	8	6.8	117.2	(50.4-230.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	31	24.5	126.4	(85.9-179.4)	Female	5	6.3	79.6	(25.6-185.7)
Female	18	22.0	81.9	(48.5-129.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	7	6.2	113.0	(45.3-232.9)
Male	7	5.0	138.9	(55.7-286.2)	Female	9	6.0	150.3	(68.6-285.3)
Female	1	1.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	91	71.9	126.6	(101.9-155.4)
Male	4	1.3	nc	(nc-nc)	<u>Stomach</u>				
Female	0	1.1	nc	(nc-nc)	Male	7	4.7	148.4	(59.4-305.8)
<u>Kidney & Renal Pelvis</u>					Female	1	2.5	nc	(nc-nc)
Male	14	9.5	146.8	(80.2-246.4)	<u>Testis</u>				
Female	6	5.5	109.2	(39.9-237.8)	Male	6	1.9	314.1	(114.7-683.7)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	2.9	nc	(nc-nc)	Male	3	3.2	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	8	10.1	79.1	(34.1-156.0)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	8	6.6	121.6	(52.3-239.6)	Female	15	14.7	101.8	(56.9-167.8)
Female	7	4.6	150.6	(60.3-310.4)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	316	255.4	123.7	(110.5-138.2)
Male	2	4.8	nc	(nc-nc)	Female	245	227.6	107.6	(94.6-122.0)
Female	3	1.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	32	36.9	86.8	(59.3-122.5)					
Female	48	34.2	140.3	(103.4-186.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Mattapoisett

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	8.9	89.9	(38.7-177.1)	Male	10	5.5	182.1	(87.2-335.0)
Female	1	3.2	nc	(nc-nc)	Female	4	4.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.6	nc	(nc-nc)	Male	4	1.4	nc	(nc-nc)
Female	3	1.3	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	4.7	nc	(nc-nc)
Female	19	31.5	60.3	(36.3-94.1)	Female	3	4.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.2	nc	(nc-nc)	Male	5	3.4	146.4	(47.2-341.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	10	11.3	88.8	(42.5-163.4)	Female	4	3.1	nc	(nc-nc)
Female	13	10.5	123.2	(65.6-210.7)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	0	2.4	nc	(nc-nc)	Male	34	34.7	98.1	(67.9-137.1)
Female	2	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	1	0.6	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	4.5	nc	(nc-nc)	Female	5	7.3	68.8	(22.2-160.5)
Female	2	2.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	1.4	nc	(nc-nc)	Female	5	7.3	68.8	(22.2-160.5)
Female	0	0.4	nc	(nc-nc)	Male	118	118.7	99.4	(82.3-119.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	3.0	nc	(nc-nc)	Female	91	108.9	83.5	(67.3-102.6)
Female	2	2.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	2.4	nc	(nc-nc)	Female	5	7.3	68.8	(22.2-160.5)
Female	0	0.8	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	13	16.5	78.6	(41.8-134.4)	Male	118	118.7	99.4	(82.3-119.1)
Female	13	15.8	82.1	(43.7-140.3)	Female	91	108.9	83.5	(67.3-102.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Maynard

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	10.3	97.0	(46.4-178.4)	Male	13	6.8	190.4	(101.3-325.6)
Female	4	4.1	nc	(nc-nc)	Female	10	5.8	173.6	(83.1-319.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.1	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	Female	3	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	7	5.9	118.3	(47.4-243.7)
Female	42	41.8	100.5	(72.4-135.9)	Female	4	5.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.8	nc	(nc-nc)	Male	2	4.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	12	13.4	89.7	(46.3-156.7)	Female	9	4.0	223.9	(102.2-425.1)
Female	12	13.8	87.1	(45.0-152.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	3.3	nc	(nc-nc)
Male	1	2.8	nc	(nc-nc)	Female	3	3.6	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	38	38.8	98.0	(69.3-134.5)
Male	0	1.0	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.8	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.5	nc	(nc-nc)
Male	4	5.6	nc	(nc-nc)	<u>Testis</u>				
Female	2	3.4	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	1.6	nc	(nc-nc)	Male	5	2.2	231.2	(74.5-539.5)
Female	0	0.5	nc	(nc-nc)	Female	6	7.2	82.8	(30.2-180.3)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	3.7	nc	(nc-nc)	Female	13	9.3	139.6	(74.2-238.7)
Female	4	3.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	139	140.1	99.2	(83.4-117.2)
Male	1	2.8	nc	(nc-nc)	Female	154	144.2	106.8	(90.6-125.1)
Female	2	1.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	18	18.8	95.6	(56.6-151.1)					
Female	18	20.0	89.9	(53.3-142.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Medfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	10.3	97.4	(46.6-179.1)	Male	14	7.4	188.3	(102.9-316.0)
Female	10	3.7	273.4	(130.9-502.9)	Female	8	5.9	136.0	(58.6-268.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.5	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)	Female	3	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	7	6.4	109.6	(43.9-225.8)
Female	57	44.2	129.0	(97.7-167.1)	Female	3	5.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.0	nc	(nc-nc)	Male	7	4.9	142.6	(57.1-293.8)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	25	14.0	178.3	(115.3-263.2)	Female	3	4.1	nc	(nc-nc)
Female	15	12.6	119.5	(66.8-197.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	7	3.4	206.0	(82.5-424.4)
Male	4	3.0	nc	(nc-nc)	Female	3	3.2	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	53	43.1	123.0	(92.1-160.9)
Male	2	1.0	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.8	nc	(nc-nc)	Male	0	2.6	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.4	nc	(nc-nc)
Male	4	6.2	nc	(nc-nc)	<u>Testis</u>				
Female	1	3.4	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.7	nc	(nc-nc)	Male	4	2.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	8	7.9	100.8	(43.4-198.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	4.0	124.6	(40.2-290.8)	Female	13	9.7	134.5	(71.6-230.0)
Female	1	2.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	186	150.7	123.4	(106.3-142.5)
Male	2	3.3	nc	(nc-nc)	Female	160	143.1	111.8	(95.2-130.5)
Female	1	1.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	20	19.6	102.0	(62.3-157.5)					
Female	17	18.5	91.7	(53.4-146.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Medford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	75	67.6	110.9	(87.2-139.0)	Male	41	40.1	102.2	(73.3-138.7)
Female	38	27.6	137.8	(97.5-189.2)	Female	34	33.6	101.2	(70.0-141.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	11.9	75.5	(34.5-143.4)	Male	3	10.4	nc	(nc-nc)
Female	9	10.6	84.8	(38.7-161.0)	Female	9	8.9	100.9	(46.0-191.5)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.8	nc	(nc-nc)	Male	34	35.3	96.3	(66.7-134.6)
Female	260	243.7	106.7	(94.1-120.5)	Female	29	33.9	85.5	(57.3-122.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	9	9.5	94.4	(43.1-179.2)	Male	19	23.1	82.3	(49.6-128.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	98	82.6	118.7	(96.3-144.6)	Female	19	24.3	78.2	(47.1-122.2)
Female	83	92.2	90.0	(71.7-111.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	22	20.7	106.2	(66.5-160.8)
Male	20	16.7	120.1	(73.3-185.5)	Female	15	24.7	60.8	(34.0-100.3)
Female	5	5.4	92.7	(29.9-216.3)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	178	233.7	76.2	(65.4-88.2)
Male	7	5.4	129.5	(51.9-266.8)	<u>Stomach</u>				
Female	5	4.5	111.7	(36.0-260.7)	Male	13	15.9	81.8	(43.5-139.9)
<u>Kidney & Renal Pelvis</u>					Female	8	10.5	75.9	(32.7-149.5)
Male	35	32.1	108.9	(75.8-151.4)	<u>Testis</u>				
Female	20	21.0	95.3	(58.2-147.2)	Male	3	8.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	11	9.5	116.0	(57.8-207.5)	Male	12	11.4	105.6	(54.5-184.5)
Female	4	2.8	nc	(nc-nc)	Female	44	37.7	116.7	(84.8-156.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	18	22.6	79.7	(47.2-126.0)	Female	59	54.6	108.0	(82.2-139.3)
Female	20	18.7	107.0	(65.3-165.2)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	820	854.6	96.0	(89.5-102.8)
Male	19	16.2	117.6	(70.8-183.6)	Female	889	890.3	99.9	(93.4-106.6)
Female	13	6.6	197.7	(105.2-338.1)					
<u>Lung and Bronchus</u>									
Male	125	121.8	102.6	(85.4-122.3)					
Female	123	132.1	93.1	(77.4-111.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Medway

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	9.8	102.6	(49.1-188.6)	Male	4	7.1	nc	(nc-nc)
Female	3	3.8	nc	(nc-nc)	Female	8	6.1	131.6	(56.7-259.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.4	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
Female	1	2.0	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	15	6.1	245.3	(137.2-404.7)
Female	32	43.5	73.5	(50.3-103.8)	Female	10	5.1	196.1	(93.9-360.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.0	nc	(nc-nc)	Male	4	4.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	14	13.2	105.7	(57.7-177.4)	Female	3	4.1	nc	(nc-nc)
Female	17	13.2	128.5	(74.8-205.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	6	3.2	188.1	(68.7-409.4)
Male	3	2.8	nc	(nc-nc)	Female	3	3.4	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	57	39.3	145.2	(110.0-188.1)
Male	3	1.1	nc	(nc-nc)	<u>Stomach</u>				
Female	2	0.9	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.5	nc	(nc-nc)
Male	4	5.8	nc	(nc-nc)	<u>Testis</u>				
Female	1	3.4	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.6	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	9	8.2	110.1	(50.2-208.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	3.9	nc	(nc-nc)	Female	8	9.3	86.1	(37.1-169.7)
Female	3	3.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	163	141.3	115.4	(98.3-134.5)
Male	2	3.0	nc	(nc-nc)	Female	138	145.0	95.1	(79.9-112.4)
Female	0	1.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	18	18.3	98.2	(58.2-155.3)					
Female	23	18.9	121.8	(77.2-182.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Melrose

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	30	32.7	91.8	(61.9-131.1)	Male	26	20.0	129.9	(84.8-190.3)
Female	13	13.4	97.3	(51.8-166.4)	Female	22	16.5	133.1	(83.4-201.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	11	6.0	184.0	(91.7-329.2)	Male	4	5.1	nc	(nc-nc)
Female	6	5.2	114.9	(42.0-250.1)	Female	3	4.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.9	nc	(nc-nc)	Male	26	17.5	148.4	(96.9-217.5)
Female	123	122.4	100.5	(83.5-119.9)	Female	19	16.5	115.0	(69.2-179.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	4.8	nc	(nc-nc)	Male	14	12.0	116.8	(63.8-196.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	30	41.1	73.0	(49.3-104.3)	Female	10	12.0	83.1	(39.8-152.9)
Female	53	45.4	116.9	(87.5-152.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	8	10.1	78.9	(34.0-155.4)
Male	2	8.3	nc	(nc-nc)	Female	13	12.0	108.4	(57.6-185.3)
Female	5	2.6	192.3	(62.0-448.7)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	109	116.1	93.9	(77.1-113.3)
Male	3	2.5	nc	(nc-nc)	<u>Stomach</u>				
Female	3	2.0	nc	(nc-nc)	Male	11	7.8	141.3	(70.5-252.9)
<u>Kidney & Renal Pelvis</u>					Female	2	5.2	nc	(nc-nc)
Male	25	16.2	154.5	(100.0-228.1)	<u>Testis</u>				
Female	10	10.3	96.8	(46.4-178.1)	Male	2	3.9	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	6	4.7	126.9	(46.3-276.2)	Male	7	5.8	120.7	(48.3-248.7)
Female	0	1.4	nc	(nc-nc)	Female	19	18.9	100.5	(60.5-156.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	14	11.2	125.2	(68.4-210.0)	Female	28	27.2	103.1	(68.5-149.0)
Female	4	9.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	418	422.0	99.1	(89.8-109.0)
Male	5	8.3	60.1	(19.4-140.2)	Female	450	439.2	102.5	(93.2-112.4)
Female	2	3.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	59	58.8	100.4	(76.4-129.5)					
Female	73	63.7	114.6	(89.8-144.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Mendon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	4.5	132.6	(48.4-288.6)	Male	6	3.4	177.3	(64.7-385.8)
Female	0	1.5	nc	(nc-nc)	Female	1	2.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.1	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	2	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	2.9	nc	(nc-nc)
Female	23	19.4	118.8	(75.3-178.3)	Female	2	2.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.9	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	5	6.3	79.3	(25.6-185.1)	Female	3	1.8	nc	(nc-nc)
Female	9	5.4	166.3	(75.9-315.7)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	1	1.3	nc	(nc-nc)	Male	36	18.8	191.1	(133.8-264.6)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	1	0.5	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	2.8	nc	(nc-nc)	Female	1	4.2	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.8	nc	(nc-nc)	Male	84	67.1	125.2	(99.9-155.0)
Female	0	0.2	nc	(nc-nc)	Female	64	62.5	102.4	(78.9-130.8)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	1.8	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	2	1.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	9	8.5	105.9	(48.3-201.0)	<u>All Sites / Types</u>				
Female	6	7.8	77.0	(28.1-167.7)	<u>All Sites / Types</u>				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Merrimac

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	6.3	111.6	(44.7-229.9)	Male	4	4.2	nc	(nc-nc)
Female	3	2.1	nc	(nc-nc)	Female	4	3.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.3	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.6	nc	(nc-nc)
Female	31	23.7	130.7	(88.8-185.6)	Female	3	2.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.1	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	5	8.2	61.0	(19.6-142.3)	Female	3	2.2	nc	(nc-nc)
Female	10	6.9	145.5	(69.7-267.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	2.0	nc	(nc-nc)
Male	0	1.7	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	27	24.1	111.9	(73.7-162.8)
Male	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.4	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	0.8	nc	(nc-nc)
Male	4	3.4	nc	(nc-nc)	<u>Testis</u>				
Female	3	1.9	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	1.0	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	4.3	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	2.3	nc	(nc-nc)	Female	7	5.3	132.1	(52.9-272.2)
Female	1	1.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	89	86.1	103.4	(83.1-127.3)
Male	0	1.8	nc	(nc-nc)	Female	87	78.3	111.1	(89.0-137.0)
Female	0	0.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	15	11.5	129.9	(72.7-214.3)					
Female	14	10.6	132.0	(72.1-221.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Methuen

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	64	49.7	128.8	(99.2-164.5)	Male	24	30.6	78.3	(50.2-116.6)
Female	19	20.1	94.6	(56.9-147.8)	Female	22	25.5	86.1	(54.0-130.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	9.5	94.8	(43.3-180.1)	Male	7	7.8	90.1	(36.1-185.6)
Female	8	8.2	97.7	(42.0-192.4)	Female	9	6.5	137.5	(62.8-261.1)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.4	nc	(nc-nc)	Male	20	27.0	74.0	(45.2-114.3)
Female	185	185.3	99.8	(86.0-115.3)	Female	18	25.0	71.9	(42.6-113.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	7.5	80.1	(29.2-174.3)	Male	14	18.2	77.1	(42.1-129.3)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	72	62.1	116.0	(90.8-146.1)	Female	13	18.2	71.4	(38.0-122.1)
Female	61	67.8	90.0	(68.8-115.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	21	15.4	136.2	(84.2-208.1)
Male	15	12.6	119.4	(66.8-196.9)	Female	19	18.0	105.8	(63.7-165.2)
Female	5	3.9	127.3	(41.0-297.1)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	177	174.7	101.3	(86.9-117.4)
Male	2	4.2	nc	(nc-nc)	<u>Stomach</u>				
Female	3	3.4	nc	(nc-nc)	Male	10	11.8	84.6	(40.5-155.5)
<u>Kidney & Renal Pelvis</u>					Female	9	7.7	116.8	(53.3-221.7)
Male	32	24.7	129.4	(88.5-182.6)	<u>Testis</u>				
Female	14	15.7	89.3	(48.8-149.8)	Male	10	6.6	152.0	(72.8-279.6)
<u>Larynx</u>					<u>Thyroid</u>				
Male	14	7.2	195.5	(106.8-328.1)	Male	7	9.1	77.2	(30.9-159.1)
Female	2	2.1	nc	(nc-nc)	Female	37	29.7	124.7	(87.8-171.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	15	17.4	86.4	(48.3-142.5)	Female	50	40.9	122.2	(90.7-161.2)
Female	12	14.1	85.0	(43.9-148.6)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	647	642.8	100.7	(93.1-108.7)
Male	14	12.6	111.3	(60.8-186.7)	Female	679	665.6	102.0	(94.5-110.0)
Female	3	4.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	73	89.7	81.4	(63.8-102.3)					
Female	95	96.4	98.5	(79.7-120.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Middleborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	35	18.8	186.5	(129.9-259.4)	Male	26	12.9	202.3	(132.1-296.4)
Female	14	7.2	193.6	(105.7-324.8)	Female	13	10.7	121.3	(64.5-207.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	4.2	143.5	(52.4-312.4)	Male	1	3.1	nc	(nc-nc)
Female	6	3.4	177.3	(64.7-385.9)	Female	4	2.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.5	nc	(nc-nc)	Male	20	11.2	178.8	(109.2-276.2)
Female	72	76.0	94.7	(74.1-119.2)	Female	9	9.5	95.1	(43.4-180.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	3.4	148.1	(47.7-345.5)	Male	10	8.1	123.5	(59.1-227.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	33	24.8	133.0	(91.6-186.8)	Female	11	7.3	150.2	(74.9-268.8)
Female	24	24.8	96.8	(62.0-144.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	6	6.0	99.3	(36.3-216.2)
Male	12	5.2	231.4	(119.4-404.3)	Female	7	6.4	108.5	(43.5-223.6)
Female	3	1.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	91	73.0	124.6	(100.3-153.0)
Male	3	2.0	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.6	nc	(nc-nc)	Male	5	4.6	108.8	(35.1-253.8)
<u>Kidney & Renal Pelvis</u>					Female	1	2.8	nc	(nc-nc)
Male	17	10.5	161.9	(94.2-259.2)	<u>Testis</u>				
Female	9	6.1	147.9	(67.5-280.9)	Male	5	3.3	153.7	(49.5-358.6)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	3.0	nc	(nc-nc)	Male	4	4.2	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	16	13.7	117.1	(66.9-190.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	12	7.1	169.8	(87.6-296.6)	Female	20	16.8	119.1	(72.7-183.9)
Female	4	5.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	377	262.4	143.7	(129.5-158.9)
Male	5	5.5	91.6	(29.5-213.9)	Female	301	261.2	115.2	(102.6-129.0)
Female	2	1.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	54	34.7	155.8	(117.1-203.3)					
Female	52	35.4	147.1	(109.8-192.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Middlefield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.6	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	3	2.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	0.8	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	1	2.4	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.0	nc	(nc-nc)	Male	1	0.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.1	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.2	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	7	8.4	83.7	(33.5-172.5)
Male	0	0.2	nc	(nc-nc)	Female	5	6.7	75.1	(24.2-175.2)
Female	0	0.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	1	1.1	nc	(nc-nc)					
Female	0	0.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Middleton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	8.0	99.8	(43.0-196.6)	Male	6	5.9	101.7	(37.1-221.4)
Female	5	2.6	191.2	(61.6-446.3)	Female	5	3.9	128.7	(41.5-300.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.0	nc	(nc-nc)	Male	4	1.4	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	6	5.1	118.5	(43.3-257.9)
Female	36	29.0	124.2	(87.0-171.9)	Female	6	3.4	174.1	(63.6-378.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.2	nc	(nc-nc)	Male	1	3.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	7	10.8	65.0	(26.0-133.9)	Female	2	2.8	nc	(nc-nc)
Female	4	8.7	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	2.6	nc	(nc-nc)
Male	2	2.2	nc	(nc-nc)	Female	2	2.3	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	41	31.5	130.0	(93.3-176.3)
Male	2	1.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.5	nc	(nc-nc)	Male	0	2.0	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	0.9	nc	(nc-nc)
Male	2	4.7	nc	(nc-nc)	<u>Testis</u>				
Female	2	2.3	nc	(nc-nc)	Male	0	2.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	1.3	nc	(nc-nc)	Male	0	2.1	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	5	5.0	99.5	(32.1-232.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	3.1	nc	(nc-nc)	Female	8	6.6	120.7	(52.0-237.9)
Female	3	1.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	125	115.8	108.0	(89.9-128.6)
Male	5	2.4	208.6	(67.2-486.8)	Female	112	96.9	115.5	(95.1-139.0)
Female	0	0.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	16	14.9	107.4	(61.3-174.4)					
Female	22	13.4	164.1	(102.8-248.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Milford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	44	26.6	165.5	(120.2-222.2)	Male	12	17.6	68.2	(35.2-119.2)
Female	10	10.8	92.2	(44.1-169.6)	Female	12	15.0	79.9	(41.2-139.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	5.6	nc	(nc-nc)	Male	5	4.3	116.0	(37.4-270.6)
Female	7	4.7	147.9	(59.2-304.7)	Female	5	3.6	140.5	(45.3-327.9)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.8	nc	(nc-nc)	Male	9	15.3	58.8	(26.8-111.6)
Female	96	106.5	90.2	(73.0-110.1)	Female	15	13.8	108.3	(60.6-178.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	7	4.6	152.0	(60.9-313.1)	Male	9	10.8	83.1	(37.9-157.8)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	39	34.4	113.4	(80.6-155.0)	Female	7	10.4	67.4	(27.0-138.8)
Female	38	37.4	101.7	(72.0-139.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	7	8.5	82.8	(33.2-170.6)
Male	10	7.1	140.5	(67.3-258.4)	Female	10	9.7	102.8	(49.2-189.0)
Female	3	2.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	120	99.7	120.4	(99.8-144.0)
Male	4	2.6	nc	(nc-nc)	<u>Stomach</u>				
Female	1	2.1	nc	(nc-nc)	Male	9	6.4	139.6	(63.7-265.1)
<u>Kidney & Renal Pelvis</u>					Female	4	4.2	nc	(nc-nc)
Male	20	14.3	139.8	(85.3-215.9)	<u>Testis</u>				
Female	8	8.7	91.9	(39.6-181.2)	Male	3	4.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	4.1	nc	(nc-nc)	Male	6	5.6	106.9	(39.1-232.8)
Female	1	1.2	nc	(nc-nc)	Female	19	18.3	103.6	(62.3-161.8)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	11	9.7	113.2	(56.4-202.6)	Female	13	23.5	55.3	(29.4-94.6)
Female	9	7.9	113.4	(51.8-215.3)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	407	361.7	112.5	(101.9-124.0)
Male	6	7.4	81.2	(29.7-176.8)	Female	351	375.0	93.6	(84.1-103.9)
Female	2	2.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	60	48.8	123.1	(93.9-158.4)					
Female	52	51.7	100.5	(75.1-131.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Millbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	15.6	115.7	(68.5-182.8)	Male	9	9.8	91.9	(41.9-174.5)
Female	11	6.3	174.2	(86.8-311.7)	Female	1	8.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	3.0	168.6	(54.3-393.3)	Male	2	2.5	nc	(nc-nc)
Female	2	2.5	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	11	8.5	128.7	(64.2-230.3)
Female	60	58.7	102.3	(78.1-131.7)	Female	5	7.8	63.8	(20.6-148.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	2.4	nc	(nc-nc)	Male	7	6.0	117.3	(47.0-241.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	22	19.8	111.3	(69.7-168.5)	Female	6	5.8	103.6	(37.8-225.6)
Female	17	21.4	79.4	(46.2-127.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	4.9	nc	(nc-nc)
Male	4	4.1	nc	(nc-nc)	Female	9	5.7	159.1	(72.6-302.0)
Female	1	1.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	53	57.6	92.1	(69.0-120.4)
Male	2	1.3	nc	(nc-nc)	<u>Stomach</u>				
Female	0	1.0	nc	(nc-nc)	Male	6	3.7	161.2	(58.9-350.9)
<u>Kidney & Renal Pelvis</u>					Female	3	2.4	nc	(nc-nc)
Male	10	8.0	125.8	(60.2-231.3)	<u>Testis</u>				
Female	8	4.9	162.9	(70.1-320.9)	Male	2	2.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	2.3	nc	(nc-nc)	Male	4	2.9	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	7	9.3	75.4	(30.2-155.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	5.4	nc	(nc-nc)	Female	15	13.2	114.0	(63.7-188.0)
Female	5	4.4	114.2	(36.8-266.4)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	218	205.9	105.9	(92.3-120.9)
Male	3	4.1	nc	(nc-nc)	Female	220	209.8	104.9	(91.5-119.7)
Female	1	1.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	32	28.3	113.2	(77.4-159.8)					
Female	39	30.2	129.2	(91.9-176.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Millis

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	6.5	107.7	(43.2-221.9)	Male	7	4.8	147.3	(59.0-303.6)
Female	3	2.4	nc	(nc-nc)	Female	8	4.0	199.7	(86.0-393.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.6	nc	(nc-nc)	Male	4	1.1	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	4.0	nc	(nc-nc)
Female	37	29.4	125.9	(88.7-173.6)	Female	3	3.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.3	nc	(nc-nc)	Male	5	3.1	160.6	(51.7-374.7)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	10	8.9	112.1	(53.7-206.2)	Female	3	2.7	nc	(nc-nc)
Female	8	8.1	99.0	(42.6-195.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	2.2	nc	(nc-nc)
Male	4	1.9	nc	(nc-nc)	Female	0	2.1	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	29	27.8	104.2	(69.8-149.7)
Male	1	0.7	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.6	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.9	nc	(nc-nc)
Male	3	4.0	nc	(nc-nc)	<u>Testis</u>				
Female	2	2.2	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.1	nc	(nc-nc)	Male	4	1.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	6	5.5	109.2	(39.9-237.8)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	2.5	nc	(nc-nc)	Female	3	6.5	nc	(nc-nc)
Female	6	1.9	318.0	(116.1-692.1)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	110	96.4	114.1	(93.8-137.5)
Male	1	2.1	nc	(nc-nc)	Female	109	95.1	114.6	(94.1-138.3)
Female	0	0.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	11	12.5	88.2	(43.9-157.7)					
Female	15	12.5	120.3	(67.3-198.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Millville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.9	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	6	8.6	69.7	(25.4-151.7)	Female	0	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	2.6	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	1	2.5	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.5	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male				
Male	0	0.3	nc	(nc-nc)	Female	10	7.7	130.5	(62.5-240.1)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	1	1.2	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male				
Male	0	0.3	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	0.8	nc	(nc-nc)	Female	2	1.8	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	0	0.6	nc	(nc-nc)	Female	3	1.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	1	3.5	nc	(nc-nc)	Female	24	28.0	85.8	(55.0-127.7)
Female	7	3.7	188.2	(75.4-387.9)	Female	27	28.8	93.9	(61.9-136.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Milton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	27	30.4	88.8	(58.5-129.3)	Male	34	18.5	183.6	(127.1-256.6)
Female	7	12.3	56.9	(22.8-117.2)	Female	23	15.5	148.9	(94.3-223.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	5.7	88.3	(28.5-206.1)	Male	8	4.8	167.7	(72.2-330.5)
Female	4	4.9	nc	(nc-nc)	Female	9	4.0	224.3	(102.3-425.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.8	nc	(nc-nc)	Male	17	16.4	103.8	(60.5-166.3)
Female	142	114.8	123.7	(104.2-145.8)	Female	22	15.3	143.8	(90.1-217.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	4.5	111.4	(35.9-260.0)	Male	10	11.1	90.0	(43.1-165.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	41	38.1	107.5	(77.1-145.8)	Female	15	11.2	133.8	(74.8-220.7)
Female	33	42.1	78.4	(54.0-110.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	6	9.4	63.6	(23.2-138.5)
Male	6	7.7	78.3	(28.6-170.4)	Female	8	11.1	72.2	(31.1-142.2)
Female	4	2.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	107	106.8	100.2	(82.1-121.0)
Male	2	2.3	nc	(nc-nc)	<u>Stomach</u>				
Female	3	2.0	nc	(nc-nc)	Male	5	7.2	69.0	(22.3-161.1)
<u>Kidney & Renal Pelvis</u>					Female	4	4.8	nc	(nc-nc)
Male	18	15.1	119.6	(70.8-189.0)	<u>Testis</u>				
Female	12	9.5	125.8	(64.9-219.7)	Male	5	3.4	145.7	(47.0-340.1)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	4.4	nc	(nc-nc)	Male	11	5.4	205.4	(102.4-367.6)
Female	1	1.3	nc	(nc-nc)	Female	20	17.7	113.0	(69.0-174.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	9	10.6	85.2	(38.9-161.7)	Female	23	25.0	91.9	(58.2-137.9)
Female	9	8.6	104.3	(47.6-198.1)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	387	391.3	98.9	(89.3-109.3)
Male	11	7.7	142.5	(71.0-255.0)	Female	442	408.4	108.2	(98.4-118.8)
Female	3	3.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	37	54.7	67.7	(47.7-93.3)					
Female	58	58.6	99.1	(75.2-128.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Monroe

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	3	0.4	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					<u>Thyroid</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Leukemia</u>					<u>Male</u>				
Male	0	0.0	nc	(nc-nc)	5	1.2	432.0	(139.2-1008.0)	
Female	0	0.0	nc	(nc-nc)	<u>Female</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					0				
Male	0	0.0	nc	(nc-nc)	1.7				
Female	0	0.0	nc	(nc-nc)	nc				
<u>Lung and Bronchus</u>					<u>Male</u>				
Male	1	0.1	nc	(nc-nc)	5				
Female	0	0.2	nc	(nc-nc)	0				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Monson

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	8.3	nc	(nc-nc)	Male	10	5.8	173.6	(83.1-319.3)
Female	4	3.0	nc	(nc-nc)	Female	6	4.6	131.7	(48.1-286.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	1.8	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	5.0	nc	(nc-nc)
Female	32	33.3	96.2	(65.8-135.7)	Female	4	4.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.4	nc	(nc-nc)	Male	8	3.7	214.6	(92.4-422.8)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	12	11.0	108.9	(56.2-190.3)	Female	4	3.2	nc	(nc-nc)
Female	10	10.3	97.4	(46.6-179.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	2.7	185.2	(59.7-432.3)
Male	0	2.4	nc	(nc-nc)	Female	6	2.7	224.1	(81.8-487.8)
Female	1	0.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	42	33.6	125.0	(90.1-169.0)
Male	3	0.8	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.6	nc	(nc-nc)	Male	4	2.0	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.1	nc	(nc-nc)
Male	4	4.8	nc	(nc-nc)	<u>Testis</u>				
Female	1	2.6	nc	(nc-nc)	Male	3	1.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.4	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	1	5.9	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	3.1	nc	(nc-nc)	Female	4	7.5	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	129	117.9	109.5	(91.4-130.1)
Male	1	2.5	nc	(nc-nc)	Female	106	111.8	94.8	(77.6-114.6)
Female	0	0.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	17	15.5	109.5	(63.8-175.3)					
Female	15	15.1	99.4	(55.6-164.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Montague

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	10.0	50.0	(16.1-116.8)	Male	2	6.2	nc	(nc-nc)
Female	3	4.0	nc	(nc-nc)	Female	2	5.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.9	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	0	1.6	nc	(nc-nc)	Female	3	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	2	5.4	nc	(nc-nc)
Female	39	36.8	105.8	(75.3-144.7)	Female	5	4.9	101.4	(32.7-236.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.4	nc	(nc-nc)	Male	0	3.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	14	12.5	111.6	(61.0-187.3)	Female	6	3.6	164.6	(60.1-358.4)
Female	12	13.2	91.1	(47.0-159.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	6	3.1	192.5	(70.3-418.9)
Male	5	2.6	194.1	(62.6-453.0)	Female	4	3.5	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	26	36.2	71.8	(46.9-105.2)
Male	2	0.8	nc	(nc-nc)	<u>Stomach</u>				
Female	2	0.7	nc	(nc-nc)	Male	4	2.4	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.5	nc	(nc-nc)
Male	4	5.0	nc	(nc-nc)	<u>Testis</u>				
Female	3	3.1	nc	(nc-nc)	Male	3	1.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	1.5	nc	(nc-nc)	Male	3	1.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	5.8	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	3.4	nc	(nc-nc)	Female	9	8.4	107.5	(49.0-204.1)
Female	3	2.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	107	130.5	82.0	(67.2-99.1)
Male	0	2.6	nc	(nc-nc)	Female	120	131.7	91.1	(75.5-108.9)
Female	0	1.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	19	18.2	104.7	(63.0-163.4)					
Female	19	19.4	98.1	(59.0-153.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Monterey

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.4	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.2	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	7	4.5	157.1	(62.9-323.7)	Female	0	0.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	1.8	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	7	5.6	124.1	(49.7-255.7)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	0	0.7	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	0.5	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.4	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	3	2.6	nc	(nc-nc)	Male	20	18.9	105.8	(64.6-163.4)
Female	0	2.1	nc	(nc-nc)	Female	12	14.6	82.3	(42.5-143.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Montgomery

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.8	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	2	3.0	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	1.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	1	0.2	nc	(nc-nc)	Male	2	3.6	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.5	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Male</u>				
Male	0	0.1	nc	(nc-nc)	Obs	10	12.0	83.6	(40.0-153.7)
Female	0	0.0	nc	(nc-nc)	<u>Female</u>				
<u>Leukemia</u>					Obs				
Male	0	0.3	nc	(nc-nc)	7	9.6	72.7	(29.1-149.8)	
Female	0	0.2	nc	(nc-nc)	<u>Male</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					10				
Male	0	0.3	nc	(nc-nc)	<u>Female</u>				
Female	0	0.1	nc	(nc-nc)	7				
<u>Lung and Bronchus</u>					<u>Male</u>				
Male	5	1.6	319.9	(103.1-746.4)	<u>Female</u>				
Female	2	1.3	nc	(nc-nc)	7				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Mount Washington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	0	1.0	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.1	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	3	3.5	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	1	0.5	nc	(nc-nc)					
Female	0	0.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Nahant

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	6.0	134.3	(57.8-264.7)	Male	5	3.5	144.7	(46.6-337.6)
Female	1	2.0	nc	(nc-nc)	Female	2	2.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.0	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
Female	19	18.6	102.0	(61.4-159.4)	Female	1	2.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.7	nc	(nc-nc)	Male	5	2.1	240.8	(77.6-562.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	6	7.4	81.6	(29.8-177.7)	Female	4	1.8	nc	(nc-nc)
Female	8	6.7	118.9	(51.2-234.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	1.8	nc	(nc-nc)
Male	2	1.5	nc	(nc-nc)	Female	0	1.8	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	18	20.5	87.6	(51.9-138.4)
Male	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	0.8	nc	(nc-nc)
Male	0	2.8	nc	(nc-nc)	<u>Testis</u>				
Female	1	1.5	nc	(nc-nc)	Male	2	0.5	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	0.8	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	2	2.8	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	1.9	258.3	(83.2-602.7)	Female	1	4.2	nc	(nc-nc)
Female	3	1.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	77	74.4	103.4	(81.6-129.3)
Male	2	1.5	nc	(nc-nc)	Female	63	65.6	96.1	(73.8-122.9)
Female	1	0.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	10	10.6	94.5	(45.2-173.7)					
Female	13	9.5	137.2	(73.0-234.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Nantucket

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	8.5	105.8	(48.3-200.9)	Male	18	6.1	294.0	(174.1-464.7)
Female	8	3.2	252.4	(108.7-497.4)	Female	6	5.0	120.6	(44.0-262.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.0	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	8	5.2	152.7	(65.8-300.9)
Female	42	33.8	124.2	(89.5-167.8)	Female	3	4.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	1.6	nc	(nc-nc)	Male	2	3.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	20	11.3	177.0	(108.1-273.4)	Female	7	3.2	216.1	(86.6-445.3)
Female	20	10.6	188.2	(114.9-290.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	2.7	nc	(nc-nc)
Male	4	2.4	nc	(nc-nc)	Female	2	2.8	nc	(nc-nc)
Female	3	0.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	84	33.4	251.2	(200.4-311.0)
Male	2	1.1	nc	(nc-nc)	<u>Stomach</u>				
Female	2	0.8	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.2	nc	(nc-nc)
Male	1	4.9	nc	(nc-nc)	<u>Testis</u>				
Female	2	2.7	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.4	nc	(nc-nc)	Male	5	2.2	231.3	(74.6-539.9)
Female	0	0.4	nc	(nc-nc)	Female	0	6.7	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	3.2	nc	(nc-nc)	Female	7	7.4	95.0	(38.0-195.7)
Female	3	2.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	193	121.5	158.8	(137.2-182.8)
Male	1	2.5	nc	(nc-nc)	Female	140	116.4	120.3	(101.2-142.0)
Female	1	0.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	17	16.0	106.4	(61.9-170.3)					
Female	12	15.9	75.6	(39.0-132.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Natick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	30	35.2	85.1	(57.4-121.5)	Male	29	22.5	129.1	(86.4-185.4)
Female	23	14.2	162.4	(102.9-243.8)	Female	13	18.9	68.8	(36.6-117.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	14	6.9	201.9	(110.3-338.8)	Male	7	5.6	124.1	(49.7-255.8)
Female	6	6.0	100.8	(36.8-219.4)	Female	3	4.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.0	nc	(nc-nc)	Male	19	19.5	97.6	(58.7-152.4)
Female	138	138.0	100.0	(84.0-118.1)	Female	11	17.9	61.6	(30.7-110.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	5.8	nc	(nc-nc)	Male	12	13.6	88.3	(45.6-154.3)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	45	44.7	100.7	(73.4-134.7)	Female	16	13.4	119.3	(68.1-193.7)
Female	44	47.7	92.3	(67.1-123.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	14	11.1	126.3	(69.0-211.9)
Male	5	9.3	53.9	(17.4-125.8)	Female	13	12.6	103.1	(54.8-176.3)
Female	2	2.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	148	131.8	112.3	(94.9-131.9)
Male	2	3.0	nc	(nc-nc)	<u>Stomach</u>				
Female	1	2.4	nc	(nc-nc)	Male	6	8.4	71.0	(25.9-154.6)
<u>Kidney & Renal Pelvis</u>					Female	4	5.4	nc	(nc-nc)
Male	19	18.3	103.7	(62.4-161.9)	<u>Testis</u>				
Female	7	11.4	61.2	(24.5-126.2)	Male	4	4.8	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	6	5.3	112.8	(41.2-245.5)	Male	8	6.8	117.0	(50.4-230.5)
Female	2	1.6	nc	(nc-nc)	Female	31	22.8	135.9	(92.3-192.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	13	12.3	105.3	(56.0-180.1)	Female	19	30.8	61.7	(37.1-96.3)
Female	11	10.1	109.3	(54.5-195.6)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	477	470.4	101.4	(92.5-110.9)
Male	4	9.3	nc	(nc-nc)	Female	469	484.7	96.8	(88.2-105.9)
Female	0	3.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	51	64.9	78.5	(58.5-103.3)					
Female	71	69.1	102.8	(80.3-129.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Needham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	37	37.5	98.7	(69.5-136.1)	Male	30	22.2	134.9	(91.0-192.6)
Female	11	15.4	71.4	(35.6-127.8)	Female	26	18.0	144.3	(94.2-211.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	6.6	75.5	(24.3-176.2)	Male	9	5.8	154.5	(70.5-293.4)
Female	7	5.8	121.4	(48.6-250.2)	Female	4	5.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.0	nc	(nc-nc)	Male	25	19.7	127.1	(82.2-187.6)
Female	164	135.8	120.7	(103.0-140.7)	Female	33	18.8	176.0	(121.1-247.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	5.1	98.3	(31.7-229.4)	Male	13	13.3	98.0	(52.1-167.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	41	46.6	88.0	(63.1-119.3)	Female	8	13.4	59.5	(25.6-117.2)
Female	49	53.2	92.0	(68.1-121.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	13	11.6	112.5	(59.8-192.4)
Male	7	9.3	75.2	(30.1-154.9)	Female	15	14.0	107.2	(59.9-176.8)
Female	2	3.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	152	130.1	116.8	(99.0-136.9)
Male	3	2.5	nc	(nc-nc)	<u>Stomach</u>				
Female	4	2.1	nc	(nc-nc)	Male	6	8.9	67.6	(24.7-147.2)
<u>Kidney & Renal Pelvis</u>					Female	4	6.2	nc	(nc-nc)
Male	14	18.1	77.4	(42.3-129.9)	<u>Testis</u>				
Female	6	11.4	52.6	(19.2-114.5)	Male	4	3.5	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	7	5.3	131.6	(52.7-271.2)	Male	14	6.1	227.8	(124.4-382.2)
Female	2	1.6	nc	(nc-nc)	Female	25	19.5	128.0	(82.8-188.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	13	12.7	102.1	(54.3-174.6)	Female	31	29.9	103.8	(70.5-147.3)
Female	12	10.6	113.3	(58.5-198.0)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	476	474.8	100.3	(91.5-109.7)
Male	8	9.3	86.5	(37.2-170.4)	Female	514	493.0	104.3	(95.4-113.7)
Female	2	3.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	40	67.0	59.7	(42.7-81.3)					
Female	59	71.1	83.0	(63.2-107.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

New Ashford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.1	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	4	0.9	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.1	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	0	0.4	nc	(nc-nc)	Male	7	3.3	212.5	(85.1-437.9)
Female	0	0.4	nc	(nc-nc)	Female	4	3.0	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

New Bedford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	108	104.1	103.7	(85.1-125.2)	Male	32	62.9	50.9	(34.8-71.8)
Female	42	44.1	95.3	(68.7-128.8)	Female	24	54.5	44.1	(28.2-65.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	16	19.4	82.3	(47.0-133.6)	Male	13	16.1	80.9	(43.0-138.4)
Female	24	17.6	136.0	(87.1-202.4)	Female	15	14.2	105.4	(59.0-173.9)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	2.9	nc	(nc-nc)	Male	51	55.6	91.8	(68.3-120.7)
Female	312	387.9	80.4	(71.7-89.9)	Female	42	54.4	77.2	(55.6-104.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	26	15.5	167.7	(109.5-245.7)	Male	55	36.5	150.7	(113.5-196.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	132	128.4	102.8	(86.0-121.9)	Female	34	38.8	87.6	(60.6-122.4)
Female	145	148.5	97.7	(82.4-114.9)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	31	25.8	120.0	(81.5-170.4)	Male	389	361.9	107.5	(97.1-118.7)
Female	6	8.6	69.9	(25.5-152.1)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	10	9.1	110.1	(52.7-202.5)	Male	12	14.1	85.1	(43.9-148.6)
Female	9	7.5	119.6	(54.6-227.0)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	59	50.3	117.2	(89.2-151.2)	Female	83	86.4	96.0	(76.5-119.1)
Female	38	33.4	113.6	(80.4-156.0)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	18	14.7	122.1	(72.3-193.0)	Male	1419	1330.8	106.6	(101.1-112.3)
Female	6	4.5	133.2	(48.6-289.9)	Female	1264	1425.5	88.7	(83.8-93.7)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	39	36.2	107.9	(76.7-147.5)	<u>All Sites / Types</u>				
Female	17	30.8	55.2	(32.1-88.3)	Male	1419	1330.8	106.6	(101.1-112.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	45	25.4	177.3	(129.3-237.2)	Female	1264	1425.5	88.7	(83.8-93.7)
Female	15	10.6	141.8	(79.3-233.8)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	229	187.0	122.5	(107.1-139.4)	Male	1419	1330.8	106.6	(101.1-112.3)
Female	186	209.3	88.9	(76.5-102.6)	Female	1264	1425.5	88.7	(83.8-93.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

New Braintree

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	0.9	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	3.7	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	1.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	4	3.5	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.1	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.3	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	10	12.9	77.6	(37.2-142.8)
Male	1	0.3	nc	(nc-nc)	Female	6	12.1	49.7	(18.1-108.1)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	0	1.7	nc	(nc-nc)					
Female	2	1.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

New Marlborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.0	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	3	6.2	nc	(nc-nc)	Female	3	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	2.6	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	2	2.0	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.6	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	13	8.0	161.7	(86.0-276.5)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	2	1.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	3	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	1	0.7	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.6	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	3	3.8	nc	(nc-nc)	Male	35	27.7	126.1	(87.8-175.4)
Female	3	3.1	nc	(nc-nc)	Female	16	21.2	75.3	(43.0-122.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

New Salem

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	3	4.0	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	1.6	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.4	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	4	4.9	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.1	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<u>Testis</u>				
Female	1	0.3	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.4	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	12	16.7	71.9	(37.1-125.6)
Male	0	0.4	nc	(nc-nc)	Female	11	12.8	86.2	(43.0-154.2)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	1	2.2	nc	(nc-nc)					
Female	2	1.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;